Using IL-10NanoCap® to treat Familial Adenomatous Polyposis
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis
This study is testing a new oral treatment called FAPXIL for people with Familial Adenomatous Polyposis (FAP) to see if it can help manage polyps and lower the risk of colon cancer, and it could offer a new option for patients looking for better ways to handle their condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Therapyx, INC. NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11061252 on NIH RePORTER |
What this research studies
This research focuses on developing an oral treatment called FAPXIL, which is a sustained-release formulation of Interleukin-10 aimed at managing Familial Adenomatous Polyposis (FAP). The project builds on previous successful pre-clinical work and aims to optimize treatment protocols while ensuring safety and effectiveness. It involves extensive testing in animal models and plans to meet with the FDA to discuss the next steps towards human clinical trials. Patients may benefit from a new therapeutic option that could reduce the progression of polyps and associated colon cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Familial Adenomatous Polyposis who are at risk for developing colon cancer.
Not a fit: Patients without a diagnosis of Familial Adenomatous Polyposis or those who do not have a significant risk of colon cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel oral therapy that significantly reduces the risk of colon cancer in patients with Familial Adenomatous Polyposis.
How similar studies have performed: Previous research has shown promise in using Interleukin-10 for similar therapeutic applications, indicating potential for success in this approach.
Where this research is happening
Buffalo, United States
- Therapyx, INC. — Buffalo, United States (Active)
Researchers
- Principal investigator: Auci, Dominick — Therapyx, INC.
- Study coordinator: Auci, Dominick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.